Introduction .
Purpose .
The primary endpoint is overall survival ,  secondaryendpoints are disease-free survival ,  rate of loco-regionalrecurrence ,  and treatment-related toxicity/morbidity .
No prior or concurrent chemo- ,  immuno- ,  radio- ,  and endocrine therapy are allowed .
The primary end-point of the study is overall survival and the expected 5-year survival in RT-treated patients is 50% ,  hence ,  175 patients will be enrolled in each arm to obtain 80% power of the study related to 15% increase of 5-year survival in RT+CT treated patients .
According to the 'intention to treat' principle ,  all patients randomized will be included in the final analysis .
